Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 1:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 20,629 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Urogenital Disease Clear all
Completed Phase 1Phase 2 Interventional Results available

Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.

NCT03345485
View directory record Official record
Conditions
Small Cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer
Interventions
Tinostamustine 60mg/m2 over 30min, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min, Tinostamustine 60mg/m2 over 60min, Tinostamustine 80mg/m2 over 60min, Tinostamustine 100mg/m2 over 60min, Tinostamustine 80mg/m2 over 80min
Drug
Lead sponsor
Mundipharma Research Limited
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
5
States / cities
Los Angeles, California • Palo Alto, California • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 10, 2026, 1:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Bioavailability Study of LY2452473 and Tadalafil

NCT01401543
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
LY2452473, Tadalafil, LY900010
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 10, 2026, 1:15 PM EDT
Completed Phase 2 Interventional Results available

Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.

NCT01972217
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Olaparib, Placebo, Abiraterone, Prednisone or prednisolone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Male only
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
2
States / cities
San Diego, California • Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 10, 2026, 1:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Microsatellite Analysis of Urinary Sediment in Detecting Bladder Cancer

NCT00095589
View directory record Official record
Conditions
Bladder Cancer
Interventions
loss of heterozygosity analysis, microarray analysis, microsatellite instability analysis, cytology specimen collection procedure, laboratory biomarker analysis, computed tomography, cystoscopy
Genetic · Other · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
40 Years to 120 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
12
States / cities
Birmingham, Alabama • Stanford, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Oct 10, 2026, 1:15 PM EDT
Completed Phase 1 Interventional

A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors

NCT03775850
View directory record Official record
Conditions
Colorectal Cancer Metastatic, Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Bladder Cancer, GastroEsophageal Cancer, Renal Cell Carcinoma, MSI-H
Interventions
EDP1503, Pembrolizumab
Biological
Lead sponsor
Evelo Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
5
States / cities
Rogers, Arkansas • Sarasota, Florida • Oklahoma City, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 10, 2026, 1:15 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Trial of Patterned Oral Somatosensory Entrainment for Shortening Time to Oral Feeding

NCT01158391
View directory record Official record
Conditions
Infant, Extremely Premature, Length of Stay, Feeding
Interventions
NTrainer® Intervention, Control Intervention
Device
Lead sponsor
KC BioMediX, Inc
Industry
Eligibility
26 Weeks to 31 Weeks
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
5
States / cities
San Jose, California • The Bronx, New York • Fort Worth, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Oct 10, 2026, 1:15 PM EDT
Completed Not applicable Interventional

Sugar Text: A Randomized Controlled Trial of a Text Message Intervention for Women With Diabetes in Pregnancy

NCT01973374
View directory record Official record
Conditions
Diabetes in Pregnancy, Gestational Diabetes, Texting Interventions
Interventions
Text Message Intervention
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 20, 2015 · Synced Oct 10, 2026, 1:15 PM EDT
Completed Phase 2 Interventional

Handheld Computers to Improve Adherence to Anti-HIV Drug Regimens

NCT00053443
View directory record Official record
Conditions
HIV Infections
Interventions
Medication Reminder System/Adherence Tracker
Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 10, 2026, 1:15 PM EDT
Completed Phase 2 Interventional

Growth Hormone to Increase Immune Function in People With HIV

NCT00071240
View directory record Official record
Conditions
HIV Infections
Interventions
Somatropin (recombinant human growth hormone)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2009 · Synced Oct 10, 2026, 1:15 PM EDT
Completed Phase 2 Interventional Results available

Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney Injury

NCT04633889
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Deferoxamine, Normal saline
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 10, 2026, 1:15 PM EDT
Completed Phase 4 Interventional Results available

Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?

NCT01101750
View directory record Official record
Conditions
Cervical Cancer, Hpv, Warts
Interventions
Quadrivalent HPV for types 6, 11, 16 and 18
Biological
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
9 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 10, 2026, 1:15 PM EDT
Terminated Phase 4 Interventional

Pilot Assessment of Lopinavir/Ritonavir and Maraviroc

NCT00981318
View directory record Official record
Conditions
HIV Infections, Acquired Immunodeficiency Syndrome
Interventions
lopinavir/ritonavir plus maraviroc
Drug
Lead sponsor
Rodwick, Barry M., M.D.
Individual
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Safety Harbor, Florida
Source: ClinicalTrials.gov public record
Updated Jun 23, 2015 · Synced Oct 10, 2026, 1:15 PM EDT
Completed Phase 2 Interventional Results available

Vaginal Cuff Brachytherapy Followed by Chemotherapy in Patients With Endometrioid Cancer

NCT00542490
View directory record Official record
Conditions
Endometrial Cancer, Papillary Serous, Clear Cell Endometrial Cancer
Interventions
Vaginal Cuff Brachytherapy
Radiation
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 21, 2020 · Synced Oct 10, 2026, 1:15 PM EDT
Completed Phase 2 Interventional

Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy

NCT01442090
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Everolimus, GDC-0980
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
8
States / cities
Fort Myers, Florida • St. Petersburg, Florida • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 10, 2026, 1:15 PM EDT
Not listed Phase 3 Interventional

Efficacy of Promescent Lidocaine Spray in Men With Premature Ejaculation

NCT02241460
View directory record Official record
Conditions
Premature Ejaculation
Interventions
Placebo, Promescent Lidocaine Spray
Drug
Lead sponsor
Eugene Y Rhee, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Los Angeles, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Oct 10, 2026, 1:15 PM EDT
Completed Not applicable Interventional

Perioperative Outcome Risk Assessment With Computer Learning Enhancement

NCT05042804
View directory record Official record
Conditions
Morality, Acute Kidney Injury
Interventions
Machine learning models predicting postoperative death and acute kidney injury
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
5,114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 10, 2026, 1:15 PM EDT
Completed No phase listed Observational

Optimizing Clinical Use of Polymyxin B

NCT02682355
View directory record Official record
Conditions
Pneumonia, Blood Stream Infection, Urinary Tract Infections, Respiratory Tract Infection (Including Tracheobronchitis), Sepsis
Interventions
Not listed
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
3
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Oct 10, 2026, 1:15 PM EDT
Recruiting Phase 1Phase 2 Interventional

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

NCT04752826
View directory record Official record
Conditions
Advanced Malignancies, Ovarian Cancer, T-cell Lymphoma, Melanoma
Interventions
BI-1808, Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection, Paclitaxel 80 mg/m2 weekly
Drug
Lead sponsor
BioInvent International AB
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
3
States / cities
Duarte, California • New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 10, 2026, 1:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Screening for Endometrial Abnormalities in Overweight and Obese Women

NCT01922778
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Endometrial Biopsy
Procedure
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 10, 2026, 1:15 PM EDT
Completed Phase 2 Interventional

EPO906 Therapy in Patients With Advanced Kidney Cancer

NCT00035243
View directory record Official record
Conditions
Kidney Neoplasms
Interventions
epothilone b
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
6
States / cities
Los Angeles, California • Baltimore, Maryland • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2012 · Synced Oct 10, 2026, 1:15 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Little Lungs Study

NCT06855043
View directory record Official record
Conditions
Invasive Mechanical Ventilation, Severe Respiratory Distress Syndrome
Interventions
Calfactant, Budesonide
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
7 Days to 14 Days
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 10, 2026, 1:15 PM EDT
Withdrawn Phase 4 Interventional

Intra-Renal Therapy of Diuretic Unresponsive Acute Kidney Injury

NCT01073189
View directory record Official record
Conditions
Kidney Failures, Acute
Interventions
Intra-Renal Fenoldopam, Furosemide
Drug
Lead sponsor
Southeast Renal Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Oct 10, 2026, 1:15 PM EDT
Completed Phase 4 Interventional Results available

Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy

NCT00498368
View directory record Official record
Conditions
IgA Nephropathy
Interventions
Intravenous Rituximab, ACE/ARB, Omega-3 Fatty Acid Fish Oil Supplement
Drug · Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
5
States / cities
San Francisco, California • Rochester, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 10, 2026, 1:15 PM EDT
Terminated Phase 1 Interventional Results available

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

NCT03685591
View directory record Official record
Conditions
Breast Neoplasms, Prostate Neoplasms, Neoplasms, Squamous Cell, Melanoma, Mesothelioma, Pancreatic Neoplasms, Colorectal Neoplasms, Carcinoma, Renal Cell, Liver Neoplasms
Interventions
PF-06952229, Enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
15
States / cities
Scottsdale, Arizona • Santa Monica, California • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2024 · Synced Oct 10, 2026, 1:15 PM EDT